NGM Biopharmaceuticals, Inc. Common Stock
NGM
NGM was delisted on the 4th of April, 2024.
122 hedge funds and large institutions have $200M invested in NGM Biopharmaceuticals, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 44 increasing their positions, 43 reducing their positions, and 17 closing their positions.
1,278% more call options, than puts
Call options by funds: $124K | Put options by funds: $9K
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
2% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 43
0.73% less ownership
Funds ownership: 59.99% → 59.26% (-0.73%)
2% less funds holding
Funds holding: 124 → 122 (-2)
12% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 17
19% less capital invested
Capital invested by funds: $246M → $200M (-$45.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
+$1.65M |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$1.39M |
| 3 |
Millennium Management
New York
|
+$946K |
| 4 |
Morgan Stanley
New York
|
+$898K |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$801K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
-$4.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$3.75M |
| 3 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$1.04M |
| 4 |
Goldman Sachs
New York
|
-$873K |
| 5 |
Man Group
London,
United Kingdom
|
-$636K |
NGM Hedge Fund Activity: Q1 2023 in Review
122 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in NGM Biopharmaceuticals, Inc. Common Stock (NGM) for Q1 2023, worth a combined $200M — down 19% from $246M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of NGM and 15 opened new positions — a net loss of 2 holders — while 43 trimmed existing stakes and 44 added.
The largest buyer was Acadian Asset Management, adding an estimated $1.65M. The largest seller was Rubric Capital Management (New York), exiting entirely with an estimated $4.4M sold.
- 122 institutional investors held NGM Biopharmaceuticals, Inc. Common Stock (NGM) as of Q1 2023, down from 124 in Q4 2022.
- Funds reported $200M of NGM Biopharmaceuticals, Inc. Common Stock stock for Q1 2023, down 19% quarter-over-quarter.
- 15 funds opened new NGM Biopharmaceuticals, Inc. Common Stock positions in Q1 2023 and 17 closed out, a net change of -2 holders.
- The largest NGM Biopharmaceuticals, Inc. Common Stock buyer in Q1 2023 was Acadian Asset Management, an estimated $1.65M added.
- The largest NGM Biopharmaceuticals, Inc. Common Stock seller in Q1 2023 was Rubric Capital Management (New York), an estimated $4.4M sold.
Based on aggregated 13F filings for Q1 2023.